Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Philip Sangster

Physician Assistant Atlanta, GA Physician Assistant

NPI 1801405758 CMS profile 10620050

3485 Greystone Cir, Atlanta, GA 30341

Open in the dashboard

General payments

$8,965

398 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Philip Sangster of Atlanta, GA is reported in the CMS Open Payments database as having received $8,965 across 398 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,048 167
2024 General $3,428 158
2023 General $1,490 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Philip Sangster
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Philip Sangster were reported at $4,048. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Philip Sangster Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $1,490 $167 $52–$557 $160
2024 $3,428 $178 $55–$600 $164
2025 $4,048 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. ITI, Inc. $1,067 66 payments
  2. Alkermes, Inc. $871 36 payments
  3. Brainsway USA Inc $848 1 payment
  4. Janssen Pharmaceuticals, Inc $725 23 payments
  5. Neurocrine Biosciences, Inc. $605 29 payments
  6. Lundbeck LLC $546 28 payments
  7. Teva Pharmaceuticals USA, Inc. $510 26 payments
  8. Otsuka America Pharmaceutical, Inc. $471 23 payments
  9. Tris Pharma Inc $457 25 payments
  10. AbbVie, Inc. $420 30 payments
  11. Other $2,445 111 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $7,994 393 payments
  2. Travel and Lodging $848 1 payment
  3. Education $124 4 payments
Products named General payments · program years 2023–2025
  1. LYBALVI $871 36 payments
  2. deep tms $848 1 payment
  3. ARISTADA Cns $706 33 payments
  4. ARISTADA Cns $706 33 payments
  5. ARISTADA Cns $706 33 payments
  6. ARISTADA Cns $706 33 payments
  7. CAPLYTA Psychiatry $610 36 payments
  8. INGREZZA $605 29 payments
  9. INVEGA SUSTENNA $525 11 payments
  10. CAPLYTA Psychiatry $458 30 payments
  11. Other $5,785 276 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

398 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record